Your session is about to expire
← Back to Search
LY3473329 for Lipoprotein Disorder (KRAKEN Trial)
KRAKEN Trial Summary
This trial studies if a new drug can reduce the risk of cardiovascular events in people with high levels of Lp(a).
KRAKEN Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.KRAKEN Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the U.S. Food & Drug Administration sanctioned LY3473329 Dose 1?
"With no data yet to support efficacy, our team at Power assigned LY3473329 Dose 1 a safety score of 2 due to the fact that it is currently in Phase 2 trials."
What is the upper limit of individuals involved in this medical experiment?
"The sponsor Eli Lilly and Company needs a minimum of 233 participants to run the trial. These individuals must meet certain criteria, with trials happening at Meander Medisch Centrum in Amersfoort, Maryland; and Care Access - Baltimore in Baltimore Massachusetts."
Can individuals currently enroll in this research project?
"Affirmative. Clinicaltrials.gov has information demonstrating that this investigation is open for recruitment, with the first posting taking place on November 24th 2022 and an update occurring September 4th 2023. 233 participants from 59 medical sites are required to complete the trial."
What is the geographical extent of this experiment's management?
"Currently, this medical trial is being administered at 59 separate sites. Locations range from Amersfoort to Baltimore and Dorchester with multiple other centres in between. It's advised that participants opt for a nearby site so as not to be burdened by excessive travel requirements."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger